Ultragenyx Pharmaceutical | RARE - Operating Expenses


Ultragenyx Pharmaceutical reported $321M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
Agios Pharmaceuticals USD 141.54M 11.8M Dec/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
BioCryst Pharmaceuticals USD -387.89M 33.7M Sep/2025
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
Esperion Therapeutics USD 67.66M 3.6M Sep/2024
Immunic USD 25.73M 2.91M Sep/2024
Insmed USD 513.55M 109.86M Dec/2025
Ionis Pharmaceuticals USD 316.9M 4.69M Sep/2025
Karyopharm Therapeutics USD 61.82M 3.24M Dec/2024
Kyowa Hakko Kirin JPY 109.02B 16.08B Dec/2025
MacroGenics USD 67M 8M Sep/2025
Moderna USD 1.54B 259M Dec/2025
Neurocrine Biosciences USD 577.6M 22M Dec/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Sarepta Therapeutics USD 462.23M 33.28M Sep/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025
Xoma USD 22.84M 1.67M Sep/2024